Milestones in Ataxia

Movement Disorders

Volumn 26, Issue 6, 2011, Pages 1134-1141

  Klockgether, Thomas ^a,b   Paulson, Henry ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Ataxia; Clinical scale; DNA repair; Ion channel dysfunction; Mitochondrial dysfunction; Polyglutamine disorders

Indexed keywords

ATAXIN 1; ATAXIN 3; ATAXIN 7; PROTEIN KINASE C;

ATAXIA; ATAXIA TELANGIECTASIA; CEREBROTENDINOUS XANTHOMATOSIS; FRIEDREICH ATAXIA; MACHADO JOSEPH DISEASE; MARINESCO SJOGREN SYNDROME; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATAXIA; BIOMEDICAL RESEARCH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 79957594670     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23559     Document Type: Review

References (48)

1. Holmes G. An attempt to classify cerebellar disease, with a note on Marie's hereditary cerebellar ataxia. Brain. 1907; 30: 545-567.
2. Greenfield JG. The spino-cerebellar degenerations. Springfield, IL: Charles C. Thomas; 1954.
3. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983; 1: 1151-1155.
4. Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993; 4: 221-226.
5. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004; 3: 291-304.
6. Dürr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010; 9: 885-894.
7. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI- 3 kinase. Science. 1995; 268: 1749-1753.
8. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996; 271: 1423-1427.
9. Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 2007; 6: 245-257.
10. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol. 2007; 6: 45-55.
11. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord. 1992; 7: 193-203.
12. Dürr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: Clinical, molecular, and neuropathological features. Ann Neurol. 1996; 39: 490-499.
13. Schöls L, Amoiridis G, Büttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: Phenotypic differences in genetically defined subtypes? Ann Neurol. 1997; 42: 924-932.
14. Maciel P, Gaspar C, DeStefano AL, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet. 1995; 57: 54-61.
15. Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996; 335: 1169-1175.
16. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009; 132: 2688-2698.
17. Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry. 1989; Suppl: 78-89.
18. Abele M, Bürk K, Schöls L, et al. The aetiology of sporadic adult-onset ataxia. Brain. 2002; 125: 961-968.
19. Genis D, Matilla T, Volpini V, et al. Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology. 1995; 45: 24-30.
20. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989; 94: 79-100.
21. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998; 44: 415-422.
22. Polo JM, Calleja J, Combarros O, Berciano J. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. Brain. 1991; 114: 855-866.
23. van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology. 2002; 58: 702-708.
24. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009; 132: 1577-1588.
25. Leone M, Bottacchi E, D'Alessandro G, Kustermann S. Hereditary ataxias and paraplegias in Valle d'Aosta, Italy: a study of prevalence and disability. Acta Neurol Scand. 1995; 91: 183-187.
26. Muzaimi MB, Thomas J, Palmer-Smith S, et al. Population based study of late onset cerebellar ataxia in south east Wales. J Neurol Neurosurg Psychiatry. 2004; 75: 1129-1134.
27. Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan-a population-based epidemiological study. Cerebellum. 2008; 7: 189-197.
28. Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum. 2004; 3: 107-111.
29. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009; 24: 1111-1124.
30. Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol. 2010; 9: 94-104.
31. Schmitz-Hübsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia type 1, 2, 3, and 6. Disease severity and nonataxia symptoms. Neurology. 2008; 71: 982-989.
32. Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan-a population-based epidemiological study. Cerebellum. 2008; 7: 189-197.
33. Schmitz-Hübsch T, Tezenas du Moncel S, Berciano J, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006; 66: 1717-1720.
34. Paulsen EK, Friedman LS, Myers LM, Lynch DR. Health-related quality of life in children with Friedreich ataxia. Pediatr Neurol. 2010; 42: 335-337.
35. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005; 6: 743-755.
36. Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 2010; 67: 291-300.
37. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008; 31: 521-528.
38. Lim J, Crespo-Barreto J, Jafar-Nejad P, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature. 2008; 452: 713-718.
39. Shakkottai VG, Paulson HL. Physiologic alterations in ataxia: channeling changes into novel therapies. Arch Neurol. 2009; 66: 1196-1201.
40. Katyal S, McKinnon PJ. DNA strand breaks, neurodegeneration and aging in the brain. Mech Ageing Dev. 2008; 129: 483-491.
41. Schmucker S, Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum Mol Genet. 2010; 19: R103-R110.
42. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010; 67: 941-947.
43. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004; 10: 816-820.
44. Gottesfeld JM, Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol. 2009; 4: 775-784.
45. Watase K, Gatchel JR, Sun Y, et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007; 4: e182.
46. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain. 2010; 133: 93-104.
47. Chen X, Tang TS, Tu H, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci. 2008; 28: 12713-12724.
48. Anheim M, Fleury M, Monga B, et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics. 2010; 11: 1-12.